Although targeted treatments like epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have demonstrated promise in treating NSCLC cases with particular EGFR mutations, their long-term efficacy is severely limited by the emergence of acquired resistance, which is frequently caused by the T790M mutation in EGFR [3–5]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.